Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.49 |
| ▸ | NAAA | Q02083 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2022982 | 0.98 | LMNA (0.54) | LMNANAAAMAPTRXFP1 | |
| SCHEMBL2021408 | 0.98 | LMNA (0.54) | LMNANAAAMAPTRXFP1 | |
| SCHEMBL2021331 | 0.98 | LMNA (0.54) | LMNANAAAMAPTRXFP1 | |
| SCHEMBL2020955 | 0.98 | LMNA (0.54) | LMNANAAAMAPTRXFP1 | |
| SCHEMBL2022070 | 0.98 | LMNA (0.54) | LMNANAAAMAPTRXFP1 | |
| SCHEMBL2018455 | 0.95 | LMNA (0.62) | LMNANPC1RECQLRAB9ASMN1; SMN2 | |
| SCHEMBL982156 | 0.91 | LMNA (0.65) | LMNANPC1RECQLRAB9ASMN1; SMN2 | |
| SCHEMBL2019233 | 0.90 | TSHR (0.56) | LMNANPC1RECQLRAB9ASMN1; SMN2 | |
| SCHEMBL2023696 | 0.90 | LMNA (0.56) | LMNANPC1RECQLRAB9ASMN1; SMN2 | |
| SCHEMBL2025902 | 0.90 | LMNA (0.56) | LMNANPC1RECQLRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3838892-B1 | METHOD FOR PRODUCING ISOCYANATE | ASAHI CHEMICAL IND (JP) | 2022-10-12 | — | — | EP | disclosed |
| EP-3293173-B1 | METHOD FOR PRODUCING ISOCYANATE | ASAHI CHEMICAL IND (JP) | 2021-07-28 | — | — | EP | disclosed |
| EP-3838892-A1 | METHOD FOR PRODUCING ISOCYANATE | Asahi Kasei Kabushiki Kaisha (JP) | 2021-06-23 | — | — | EP | disclosed |
| EP-2980066-B1 | METHOD FOR PRODUCING ISOCYANATE | ASAHI CHEMICAL IND (JP) | 2021-04-21 | — | — | EP | disclosed |
| EP-3293173-A1 | METHOD FOR PRODUCING ISOCYANATE | Asahi Kasei Kabushiki Kaisha (JP) | 2018-03-14 | — | — | EP | disclosed |
| US-9714215-B2 | Method for producing isocyanate | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2017-07-25 | — | — | US | disclosed |
| US-20160052874-A1 | METHOD FOR PRODUCING ISOCYANATE | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2016-02-25 | — | — | US | disclosed |
| EP-2980066-A1 | METHOD FOR PRODUCING ISOCYANATE | Asahi Kasei Chemicals Corporation (JP) | 2016-02-03 | — | — | EP | disclosed |
| US-9145358-B2 | N-substituted carbamic acid ester production method, isocyanate production method using such N-substituted carbamic acid ester, and composition for transfer and storage of N-substituted carbamic acid ester comprising N-substituted carbamic acid ester and aromatic hydroxy compound | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2015-09-29 | — | — | US | disclosed |
| US-20140194644-A1 | N-Substituted Carbamic Acid Ester Production Method, Isocyanate Production Method Using Such N-Substituted Carbamic Acid Ester, and Composition for Transfer and Storage of N-Substituted Carbamic Acid Ester Comprising N-Substituted Carbamic Acid Ester and Aromatic Hydroxy Compound | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2014-07-10 | — | — | US | disclosed |
| US-20110160476-A1 | N-Substituted Carbamic Acid Ester Production Method and Isocyanate Production Method Using the N-Substituted Carbamic Acid Ester | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160476-A1 | N-Substituted Carbamic Acid Ester Production Method and Isocyanate Production Method Using the N-Substituted Carbamic Acid Ester | ALKBH3, CPS1, APEH | LMNA 2324/4885NPC1 895/4885RECQL 4549/4885 |
| US-20160052874-A1 | METHOD FOR PRODUCING ISOCYANATE | CPS1, ALKBH3, IDH3A | LMNA 1301/4885NPC1 553/4885RECQL 1101/4885 |
| US-20140194644-A1 | N-Substituted Carbamic Acid Ester Production Method, Isocyanate Production Method Using Such N-Substituted Carbamic Acid Ester, and Composition for Transfer and Storage of N-Substituted Carbamic Acid Ester Comprising N-Substituted Carbamic Acid Ester and Aromatic Hydroxy Compound | CPS1, ALKBH3, RCC1 | LMNA 1776/4885NPC1 477/4885RECQL 2975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.